



German company, working in the field of contract manufacturing of active pharmaceutical ingredients, is looking for commercial, supplier, manufacturing and outsourcing agreements in different countries.

Summary

| Profile type | Company's country | POD reference |
|-----------------------|-----------------------|--------------------------------|
| Business Offer | Germany | BODE20240822001 |
| | | |
| Profile status | Type of partnership | Targeted countries |
| PUBLISHED | Commercial agreement | • France |
| | Outsourcing agreement | Croatia |
| | Supplier agreement | • Czechia |
| | | Denmark |
| | | Austria |
| | | • Bulgaria |
| | | • Greece |
| | | • Estonia |
| | | • Finland |
| | | • Belgium |
| | | • Serbia |
| | | Montenegro |
| | | • Poland |
| | | • Ireland |
| | | • Italy |
| | | • Lithuania |
| | | • Romania |
| | | Luxembourg |
| | | • Iceland |
| | | • Latvia |









- Norway
- Netherlands
- Israel
- Portugal
- Slovakia
- Malta
- United Kingdom
- Slovenia
- Japan
- Spain

Contact Person

Noriko MITA

Term of validity

22 Aug 2024 22 Aug 2025 Last update

22 Aug 2024

General Information

Short summary

The company is specialized in supplying APIs (Active Pharmaceutical Ingredients) and finechemicals especially under GMP (Good Manufacturing Practice) for the pharmaceutical and biotech industry, but also for non GMP applications. Commercial routine production is available for an annual requirement of ca. 100 g to several 100 kg, for special GMP products of orphan disease APIs.

Full description

The German company, located in the South West of German, is specialized in supplying APIs and finechemicals under GMP. The FDA-inspected production facilities in Germany are optimized for g to multi kg quantities, as typically encountered in preclinical research and all clinical phases of API approval. Commercial routine production is available for an annual requirement of ca. 100 g to several 100 kg i.e. for speciality GMP products or orphan disease APIs. The company has broad chemical expertise, including synthetic route and GMP process development for organic small molecules, inorganic salts and complexes as well as medical polymers. The company is certified in the handling or carcinogenic substances and capable of handling legally controlled narcotics. Quality control, analytical development and regulatory support complete the company services. The company is offering commercial agreements, outsourcing agreements, supplier agreements, manufacturing agreements and research and development cooperation agreements for different countries.







Advantages and innovations

high chemical expertise, regulatory expertise, flexibility, projectmanagement, GMP, API, small scale, organic, from preclinics all the way to commercial supply

Technical specification or expertise sought

suitable: GMP, injection grade, pharmaceutical or biotech applications, clinical phase supply, small scale not suitable: technical grade, bulk chemicals, agrochemicals

Stage of development

Sustainable Development goals

Goal 3: Good Health and Well-being

IPR Status

Partner Sought

Expected role of the partner

The company is looking for innovative pharmaceutical or biotech companies who are looking for a supplier for their new chemcial entity (starting from small scale synthesis, over upscale all the way until GMP production, from pre-clinical phase to clinical phase III and commercial supply). The company is also looking for established or innovative pharmaceutical companies who are looking for a supplier for one of the developed products. GMP or non-GMP development is possible, especially long term with the same understanding of quality (GMP).

Type of partnership

Type and size of the partner

Commercial agreement

• SME 11-49

Outsourcing agreement

University

Supplier agreement

• SME 50 - 249

R&D Institution

• SME <=10









Dissemination

Technology keywords

• 06001015 - Pharmaceutical Products / Drugs

Market keywords

- 08001023 Other chemicals and materials (not elsewhere classified)
- 05007007 Other medical/health related (not elsewhere classified)
- 05007002 Pharmaceuticals/fine chemicals







Targeted countries

- France
- Croatia
- Czechia
- Denmark
- Austria
- Bulgaria
- Greece
- Estonia
- Finland
- Belgium
- Serbia
- Montenegro
- Poland
- Ireland
- Italy
- Lithuania
- Romania
- Luxembourg
- Iceland
- Latvia
- Norway
- Netherlands
- Israel
- Portugal
- Slovakia
- Malta
- United Kingdom
- Slovenia
- Japan
- Spain

Sector groups involved

Health

